# Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

> **NCT02959905** · PHASE1 · COMPLETED · sponsor: **BGI, China** · enrollment: 11 (actual)

## Conditions studied

- Solid Cancer

## Interventions

- **BIOLOGICAL:** TSA-CTL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02959905
- **Lead sponsor:** BGI, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-05-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959905, "Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02959905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*